2025
Henrique Tofoli Vieira Machado, Geovana Mendes de Seixas, L. Silva et al.
Introduction: In recent years, psilocybin has been explored as an alternative therapy for neurological and psychiatric disorders, such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance dependence. Studies suggest that when administered under professional supervision, psilocybin can offer relief for patients with treatment-resistant disorders. Objective: The aim of...
Psi Chi Journal of Psychological Research
2025
Madison M. H. Simounet, Joy Drinnon
Psilocybin-assisted therapies (PAT) have been used to treat several issues including obsessive-compulsive disorder (OCD), major depressive disorder (MDD), posttraumatic stress disorder (PTSD), smoking addiction, and anxiety (Grob et al., 2011; Johnson et al., 2014; Kisely et a., 2022; Moreno et al., 2006). If more positive benefits of psilocybin are discovered, psilocybin could become a more...
Alzheimer's & Dementia
2025
Mamta Sapra, Lauren Hagemann, Katherine Luci et al.
3 citations
Effective interventions are needed to reduce caregiver burden and stress, particularly among family caregivers of veterans with dementia. Unique risk factors such as traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) further complicate caregiving. This study compares a four-session mindfulness-based multicomponent intervention (PAACC) with a cognitive behavioral intervention...
The American Journal of Bioethics
2025
Logan Neitzke-Spruill, Caroline Beit, Lynnette A. Averill et al.
19 citations
In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.'s new drug application for midomafetamine with psychological intervention (MDMA-AT) to treat post-traumatic stress disorder (PTSD). Among the many issues raised during review was concern about a highly publicized case of alleged sexual misconduct by an unlicensed therapist during a Phase 2 study of MDMA and...
Iranian journal of basic medical sciences
2025
Mehrdad Hajinejad, Ahmadreza Gharaeian Morshed, Abdolreza Narouiepour et al.
1 citation
Traumatic brain injury (TBI) is a significant cause of mortality and disability worldwide. TBI has been associated with factors such as oxidative stress, neuroinflammation, and apoptosis, which are believed to be mediated by the N-methyl-D-aspartate (NMDA)-type glutamate receptor. Two NMDA receptor antagonists, ketamine and memantine, have shown potential in mitigating the pathophysiological...
Progress in Brain Research
2025
Mohamad Alfateh Abou Haykal
This chapter explores the profound impact of love and joyful memories on the brainstem, emphasizing their significance for mental and emotional well-being. It introduces the brainstem's role in essential life functions and its connection to higher emotional processes. Topics delve into the neurobiology of love, detailing how chemicals like oxytocin, dopamine, and serotonin interact with...
Frontiers in Psychology
2025
Paul F Cook, Laurra M Aagaard, Lisa Krug Avery et al.
Nursing students are at risk for traumatic stress, but current treatments have limited benefits. Regenerating Images in Memory (RIM) is a verbal psychotherapeutic approach to help people safely re-experience troubling memories, then integrate them into meaningful life narratives. RIM's developers propose a mechanism of action based on nonconscious processes like emotional processing and body...
Frontiers in Neuroscience
2025
Martin Boese, Rina Y. Berman, Kennett D. Radford et al.
5 citations
Ketamine, a multimodal dissociative anesthetic, is widely used as a trauma analgesic in emergency situations. Ketamine is also used to treat psychiatric disorders due to its broad application potential, including treatment-resistant major depression. However, its impacts on the development of post-traumatic stress disorder (PTSD) and its potential as a treatment for PTSD are controversial. PTSD...
American Journal of Psychiatry
2025
Scott T Aaronson, Andrew van der Vaart, Tammy Miller et al.
31 citations
This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.
Acta Neuropsychiatrica
2025
Isabel Werle, Marina A. M. Portes, Leandro J Bertoglio
2 citations
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use disorder, offering relatively safe profiles, enhanced efficacy, and lasting effects after a few applications. Athletes often experience high levels of stress and pressure, making them susceptible to these psychiatric conditions. However, the effects...